Allogeneic haemopoietic stem cell transplantation for non-Hodgkin's lymphoma

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 3, 2002, Pages 481-504

  Toze, Cynthia L ^a   Barnett, Michael J ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Allogeneic haemopoietic stem cell transplantation; Non Hodgkin's lymphoma

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CAMPATH 1G; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN; METHYLPREDNISOLONE;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BURKITT LYMPHOMA; CANCER GRADING; CANCER THERAPY; CHILD; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LYMPHOMA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKOCYTE; LIVING DONOR; LYMPHATIC LEUKEMIA; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PEDIATRICS; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; ALLOGRAFT; DONOR; GRAFT VERSUS LEUKEMIA EFFECT; HISTOPATHOLOGY; LYMPHOBLASTOMA; LYMPHOPROLIFERATIVE DISEASE; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; METHODOLOGY; MORTALITY; STANDARD; TREATMENT OUTCOME;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0036458422     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2002.0223     Document Type: Article

References (108)

1. Frei E & Canellos GP. Dose: a critical factor in cancer chemotherapy. American Journal of Medicine 1980; 69: 585-594.
2. Jones RJ, Ambinder RF, Piantadosi S & Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-653.
3. Goldman JM, Johnson SA, Catovsky D et al. Identical twin marrow transplantation for patients with leukemia and lymphoma. Transplantation 1981; 31: 140-141.
4. Appelbaum FR, Fefer A, Cheever MA et al. Treatment of non-Hodgkin's lymphoma with marrow transplantation in identical twins. Blood 1981; 58: 509-513.
5. Appelbaum FR, Thomas ED, Buckner CD et al. Treatment of non-Hodgkin's lymphoma with chemoradiotherapy and allogeneic marrow transplantation. Hematological Oncology 1983; 1: 149-157.
6. Elfenbein GJ, Anderson PN, Humphrey RL et al. Immune system reconstitution following allogeneic bone marrow transplantation in man: a multiparameter analysis. Transplantation Proceedings 1976; 8: 641-646.
7. Phillips GL, Herzig RH, Lazarus HM et al. High-dose chemotherapy, fractionated total-body irradiation, and allogeneic marrow transplantation for malignant lymphoma. Journal of Clinical Oncology 1986; 4: 480-488.
8. Ernst P, Maraninchi D, Jacobsen N et al. Marrow transplantation for non-Hodgkin's lymphoma: A multi-centre study from the European Co-operative Bone Marrow Transplant Group. Bone Marrow Transplantation 1986; 1: 81-86.
9. Appelbaum FR, Sullivan KM, Buckner CD et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. Journal of Clinical Oncology 1987; 5: 1340-1347.
10. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphoma: Summary and description of a working formulation for clinical usage. The non-Hodgkin's lymphoma pathologic classification project. Cancer 1982; 49: 2112-2135.
11. Nademanee AP, Forman SJ, Schmidt GM et al. Allogeneic bone marrow transplantation for high risk non-Hodgkin's lymphoma during first complete remission. Blut 1987; 55: 11-18.
12. Copelan EA, Kapoor N, Gibbins B & Tutschka PJ. Allogeneic marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplantation 1990; 5: 47-50.
13. Lundberg JH, Hansen RM, Chitambar CR et al. Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors. Journal of Clinical Oncology 1991; 9: 1848-1859.
14. Shepherd JD, Barnett MJ, Connors JM et al. Allogeneic bone marrow transplantation for poor-prognosis non-Hodgkin's lymphoma. Bone Marrow Transplantation 1993; 12: 591-596.
15. Demirer T, Weaver CH, Buckner CD et al. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. Journal of Clinical Oncology 1995; 13: 596-602.
16. Mendoza E, Territo M, Schiller G et al. Allogeneic bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplantation 1995; 15: 299-303.
17. van Besien K, Mehra RC, Giralt SA et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity, and survival depend on disease histology. American Journal of Medicine 1996; 100: 299-307.
18. Dann EJ, Daugherty CK & Larson RA. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. Bone Marrow Transplantation 1997; 20: 374-396.
19. + T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplantation 1998; 21: 1177-1181.
20. Juckett M, Rowlings P, Messner M et al. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up. Bone Marrow Transplantation 1998; 21: 893-899.
21. Przepiorka D, van Besien K, Khouri I et al. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Annals of Oncology 1999; 10: 527-532.
22. Dhedin N, Giraudier S, Gaulard P et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. British Journal of Haematology 1999; 107: 154-161.
23. Cull GM, Haynes AP, Byrne JL et al. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. British Journal of Haematology 2000; 108: 754-760.
24. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
25. Bernard M, Dauriac C, Drénou B et al. Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma. Bone Marrow Transplantation 1999; 23: 329-333.
26. Milpied N, Ifrah N, Kuentz M et al. Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission. British Journal of Haematology 1989; 73: 82-87.
27. Chopra R, Goldstone AH, Pearce R et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European bone marrow transplant group registry data. Journal of Clinical Oncology 1992; 10: 1690-1695.
28. Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-1055.
29. Stein RS, Greer JP, Goodman S et al. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. Bone Marrow Transplantation 1999; 23: 227-233.
30. Verdonck LF. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: updated results of the Utrecht experience. Leukemia and Lymphoma 1999; 34: 129-136.
31. Schimmer AD, Jamal S, Messner H et al. Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Bone Marrow Transplantation 2000; 26: 859-864.
32. Rodriguez J, Munsell M, Yazji S et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. Journal of Clinical Oncology 2001; 19: 3766-3770.
33. Lister TA, Cullen MH, Beard MEJ et al. Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. British Medical Journal 1978; 1: 533-537.
34. Glick JH, Barnes JM, Ezdinli EZ et al. Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood 1981; 58: 920-925.
35. Dana BW, Dahlberg S, Nathwani BN et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. Journal of Clinical Oncology 1993; 11: 644-651.
36. Pott-Hoeck C & Hiddemann W. Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias. Annals of Oncology 1995; 6: 421-433.
37. Micallef INM, Lillington DM, Apostolidis J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support. for lymphoid malignancies. Journal of Clinical Oncology 2000; 18: 947-955.
38. van Besien W, Khouri IF, Giralt SA et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. Journal of Clinical Oncology 1995; 13: 1096-1102.
39. Verdonck LF, Dekker AW, Lokhorst HM et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 4201-4205.
40. Mandigers CMPW, Raemaekers JMM, Schattenberg AVMB et al. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma. British Journal of Haematology 1998; 100: 198-206.
41. van Besien K, Sobocinski KA, Rowlings PA et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998; 92: 1832-1836.
42. Toze CL, Shepherd JD, Connors JM et al. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Bone Marrow Transplantation 2000; 25: 605-612.
43. Matolcsy A. High-grade transformation of low-grade non-Hodgkin's lymphomas: mechanisms of tumor progression. Leukemia and Lymphoma 1999; 34: 251-259.
44. Schouten HC, Bierman PJ, Vaughan WP et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 1989; 74: 2579-2584.
45. Chen CI, Crump M, Tsang R et al. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. British Journal of Haematology 2001; 113: 202-208.
46. Foran JM, Apostolidis J, Papamichael D et al. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Annals of Oncology 1998; 9: 865-869.
47. Rodriguez J, Keating MJ, O'Brien S et al. Allogeneic haematopoietic transplantation for Richter's syndrome. British Journal of Haematology 2000; 110: 897-899.
48. Karsan A, Gascoyne RD, Coupland RW et al. Combination of t(14;18) and a Burkitt's type translocation in B-cell malignancies. Leukemia and Lymphoma 1993; 10: 433-441.
49. Macpherson N, Lesack D, Klasa R et al. Small noncleaved, non-Burkitt's (Burkitt-like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. Journal of Clinical Oncology 1999; 17: 1558-1567.
50. Khouri IF, Lee M-S, Romaguera J et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Annals of Oncology 1999; 10: 1293-1299.
51. Sweetenham JW. Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials? Bone Marrow Transplantation 2001; 28: 813-820.
52. Magrath IT, Janus C, Edwards BK et al. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 1984; 63: 1102-1111.
53. Bernstein JI, Coleman CN, Strickler JG et al. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). Journal of Clinical Oncology 1986; 4: 847-858.
54. Soussain C, Patte C, Ostronoff M et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 1995; 85: 664-674.
55. Magrath I, Adde M, Shad A et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. Journal of Clinical Oncology 1996; 14: 925-934.
56. Todeschini G, Tecchio C, Degani D et al. Eighty-one percent event-free survival in advanced Burkitt's lymphoma/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol. Annals of Oncology 1997; 8: 577-581.
57. Willemze R, Peters WG, van Hennick MB et al. Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non-Hodgkin lymphoma. Scandinavian Journal of Haematology 1985; 34: 83-87.
58. Coleman CN, Picozzi VJ Jr, Cox RS et al. Treatment of lymphoblastic lymphoma in adults. Journal of Clinical Oncology 1986; 4: 1628-1637.
59. Peters WG, Willemze R & Colly LP. Preliminary results of consolidation therapy with high-dose cytosine arabinoside for patients with bad-risk or relapsed acute leukemia or lymphoblastic non-Hodgkin's lymphoma. European Journal of Cancer and Clinical Oncology 1987; 23: 401-405.
60. Morel P, Lepage E, Brice P et al. Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. Journal of Clinical Oncology 1992; 10: 1078-1085.
61. Zinzani PL, Bendandi M, Visani G et al. Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients. Leukemia and Lymphoma 1996; 23: 577-582.
62. Appelbaum FR, Deisseroth AB, Graw RG et al. Prolonged complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse. Cancer 1978; 41: 1059-1063.
63. Sweetenham JW, Pearce R, Taghipour G et al. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma - outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology 1996; 14: 2465-2472.
64. Baro J, Richard C, Calavia J et al. Autologous bone marrow, transplantation as consolidation therapy for non-Hodgkin's lymphoma patients with poor prognostic features. Bone Marrow Transplantation 1991; 8: 283-289.
65. Verdonck LF, Dekker AW, de Gast GC et al. Autologous bone marrow transplantation for adult poor-risk lymphoblastic lymphoma in first remission. Journal of Clinical Oncology 1992; 10: 644-646.
66. Sweetenham JW, Liberti G, Pearce R et al. High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European Group for Bone Marrow Transplantation. Journal of Clinical Oncology 1994; 12: 1358-1365.
67. Sweetenham JW, Santini G, Qian W et al High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for blood and marrow transplantation and the United Kingdom Lymphoma Group. Journal of Clinical Oncology 2001; 19: 2927-2936.
68. Troussard X, Leblond V, Milpied N et al. Allogeneic bone marrow transplantation in adults with Burkitt's lymphoma or acute lymphoblastic leukemia in first complete remission. Journal of Clinical Oncology 1990; 8: 809-812.
69. Long GD, Amylon MD, Stockerl-Goldstein KE et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biology of Blood and Marrow Transplantation 1997; 3: 324-330.
70. Ungkanont A, Mongkonsritrakoon W, Jootar S & Strichaikul T. Allogeneic stem cell transplantation in a patient with refractory Burkitt's lymphoma using non-myeloablative conditioning regimen. Bone Marrow Transplantation 2000; 26: 1351-1354.
71. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. Journal of Clinical Oncology 1999; 17: 3835-3849.
72. Lilleyman JS & Pinkerton CR. Lymphoblastic leukemia and non-Hodgkin's lymphoma. British Medical Bulletin 1996; 52: 742-763.
73. Sullivan MP & Ramirez I. Curability of Burkitt's lymphoma with high-dose cyclophosphamide-high-dose methotrexate therapy and intrathecal chemoprophylaxis. Journal of Clinical Oncology 1985; 3: 627-636.
74. +) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. Journal of Clinical Oncology 1986; 4: 1732-1739.
75. Eden OB, Hann I, Imeson J et al. Treatment of advanced stage T cell lymphoblastic lymphoma: results of the United Kingdom Children's Cancer Study Group (UKCCSG) protocol 8503. British Journal of Haematology 1992; 82: 310-316.
76. Cole CH, Pritchard S, Rogers PCJ et al. Intensive conditioning regimen for bone marrow transplantation in children with high-risk haematological malignancies. Medical and Pediatric Oncology 1994; 23: 464-469.
77. Gordon BG, Weisenburger DD, Sanger WG et al. Peripheral T-cell lymphoma in children and adolescents: role of bone marrow transplantation. Leukemia and Lymphoma 1994; 14: 1-10.
78. Ladenstein R, Pearce R, Hartmann O et al. High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood 1997; 90: 2921-2930.
79. Bureo E, Ortega JJ, Muñoz A et al. Bone marrow transplantation in 46 pediatric patients with non-Hodgkin's lymphoma. Bone Marrow Transplantation 1995; 15: 353-359.
80. O'Leary M, Ramsay NK, Nesbit ME et al. Bone marrow transplantation for non-Hodgkin's lymphoma in children and young adults. American Journal of Medicine 1983; 74: 497-501.
81. Chakravarti V, Kamani NR, Bayever E et al. Bone marrow transplantation for childhood Ki-I lymphoma. Journal of Clinical Oncology 1990; 8: 657-660.
82. Balduzzi A, Gooley T, Anasetti C et al. Unrelated donor marrow transplantation in children. Blood 1995; 86: 3247-3256.
83. Kook H, Goldman F, Padley D et al. Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: immunophenotypic analysis and factors affecting the speed of recovery. Blood 1996; 88: 1089-1097.
84. Hoffmann T, Heilmann C, Madsen HO et al. Matched unrelated allogeneic bone marrow transplantation for recurrent malignant lymphoma in a patient with X-linked lymphoproliferative disease (XLP). Bone Marrow Transplantation 1998; 22: 603-604.
85. Hale GA, Tong X, Benaim E et al. Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation. Bone Marrow Transplantation 2001; 27: 155-162.
86. Przepiorka D, Khouri I, Ippoliti C et al. Tacrolimus and miniclose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplantation 1999; 24: 763-768.
87. Liesveld JL, Duerst RE, Rapoport AP et al. Continuous infusion cyclosporine and nifedipine to day + 100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants. Bone Marrow Transplantation 1999; 24: 511-516.
88. + donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. Journal of Clinical Oncology 2001; 19: 1152-1159.
89. Tsai T, Goodman S, Saez R et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplantation 2002; 20: 859-863.
90. Vandenberghe E, Pearce R, Taghipour G et al. Role of second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Bone Marrow Registry. Journal of Clinical Oncology 1997; 15: 1595-1600.
91. Moreau P, Mechinaud F, Mahe B et al. Successful allogeneic bone marrow transplantation for early relapse after autologous bone marrow transplantation in two cases of aggressive high-grade non-Hodgkin's lymphoma. Bone Marrow Transplantation 1996; 18: 665-667.
92. de Lima M, van Besien KW, Giralt SA et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplantation 1997; 19: 121-127.
93. Schouten HC, Armitage JO, Klassen LW et al. Allogeneic bone marrow transplantation in patients with lymphoma relapsing after autologous marrow transplantation. Bone Marrow Transplantation 1989; 4: 119-121.
94. Khouri IF, Saliba RM, Giralt SA et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595-3599.
95. Or R, Ackerstein A, Nagler A et al. Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation. Journal of Immunotherapy 1998; 21: 447-453.
96. Mohty M, Fegueux N, Exbrayat C et al. Reduced intensity conditioning transplants. Enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy. Bone Marrow Transplantation 2001; 28: 335-339.
97. Carella AM, Cavaliere M, Lerma E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. Journal of Clinical Oncology 2000; 18: 3918-3924.
98. Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
99. Dey BR, McAfee S, Sackstein R et al. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biology of Blood and Marrow Transplantation 2001; 7: 604-612.
100. Michallet M, Bilger K, Garban F et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. Journal of Clinical Oncology 2001; 19: 3340-3349.
101. Korbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
102. Hägglund H, Ringdén O, Remberger M et al. Faster neutrophil and platelet engraftment, but no differences in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrow. Bone Marrow Transplantation 1998; 22: 131-136.
103. Fauser AA, Basara N, Blau IW & Kiehl MG. A comparative study of peripheral blood stem cell vs bone marrow transplantation from unrelated donors (MUD): a single center study. Bone Marrow Transplantation 2000; 25: S27-S31.
104. Gluckman E, Rocha V, Boyer-Chammard A et al. Outcome of cord-blood transplantation from related and unrelated donors. New England Journal of Medicine 1997; 337: 373-381.
105. Laughlin MJ, Barker J, Bambachi B et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. New England Journal of Medicine 2001; 344. 1815-1822.
106. van Besien KW, de Lima M, Giralt SA et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplantation 1997; 19: 977-982.
107. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow tranplantation. Blood 1996; 87: 2195-2204.
108. Meijerink JPP, Goverde GJ, Smetsers TFCM et al. Quantitation of follicular non-Hodgkin's lymphoma cells carrying t(14;18) in a patient before and after allogeneic bone marrow transplantation. Annals of Oncology 1994; 5: S43-S45.